BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

The FDA’s premarket approval green light spans one pan-cancer ... Finally, the assay can be used with Merck’s Keytruda ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... BioNTech is also exploring combinations with antibody-drug ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

application to the FDA for this program in 2025.” The per-protocol interim analysis in the pivotal Phase 3 trial (IOB-013/KN-D18), which is evaluating IO102-IO103 in combination with KEYTRUDA ® ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer ... The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy, followed by adjuvant ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

FDA approval of tarlatamab (Imdelltra ... patients with glioblastoma treated with the bivalent CAR T-cell therapy also ...